Biosite Incorporated Issues Voluntary, Nationwide Recall for Cardiac Marker Test
... SAN DIEGO, May 6 /PRNewswire/ -- biosite Incorporated has initiated a voluntary, nationwide...Cardiac Panel, Catalog No. 97000HS, Lot #W44467B. biosite Incorporated has notified its customers via overni...ining inventory of this affected product lot. biosite Incorporated has reported the action to the U.S. F...Beckman Coulter Announces Third Quarter 2008 Results
...ssified under other non-operating expenses. i) biosite break-up fee -- On May 17, 2007, the merger agreem... to acquire Biosite, Inc. was terminated by biosite in accordance with its terms. Pursuant to the terms of the agreement, biosite paid the Company a break up fee of $54 mill...Astute Medical Raises $6.2 Million in Series A Financing Round Led by De Novo Ventures
...Pherson Ph.D., former members of the management at biosite Incorporated, a leading diagnostics company acquir...ions in 2007 for $1.7 billion. Hibberd served at biosite for 10 years, most recently as senior vice president corporate development. Dr. McPherson was at biosite for fourteen years, most recently as vice presiden...Inverness Completes Acquisition of Cholestech
...to physicians and patients and we believe that this added access to physicians' office laboratories will provide broad benefits for many Inverness and biosite products," stated Ron Zwanziger, Chairman, President and Chief Executive Officer of Inverness. "We welcome Cholestech and its associates to the Invern...Biosite Reports on Presentation of Preliminary Data From Sepsis Program
... Belgium, March 28, 2007 /PRNewswire-FirstCall/ -- biosite Incorporated today announced preliminary results o...n our clinical process," said Ken Buechler, Ph.D., biosite president and chief scientific officer. "We are on...e selected from 150 biomarkers studied through the biosite Discovery program. The panel incorporates Biosite'...Liquichek Qualitative Urine Toxicology Control
Description:...l designed for use with qualitative rapid urine drug screen panels, including Point of Care (POC) Drugs of Abuse (DOA) test kits like Bio-Rad TOX/See, biosite Triage and other brands. The package insert includes qualitative results (+/) for popular kits and recovery values by gas chromatography (GC) and othe...GEN reports on growing reliance on microfluidics technology
...enzymes. It combines the advantages of capillary electrophoresis with microfluidics technology for the direct measurement of substrate and product. biosite has developed protein array technologies that contain microcapillaries for controlling the flow of fluids in immunoassay processes. The protein array ...New technology aims to reduce maternal and neonatal deaths
...reeclampsia, has been licensed to California-based biosite Inc. for further development and eventual commerci...y. This finding drew the immediate attention of biosite Inc., a division of Inverness Medical Innovations,... world leader in the area of medical diagnostics. biosite Inc. will help support the researchers' continued ...GEN Reports on Growing Reliance on Microfluidics Technology
...zymes. It combines the advantages of capillary electrophoresis with microfluidics technology for the direct measurement of substrate and product. biosite has developed protein array technologies that contain microcapillaries for controlling the flow of fluids in immunoassay processes. The protein array ...Inverness Medical Innovations Announces Third Quarter 2008 Results
...lion of in-process research and development acquired in connection with the biosite acquisition, $0.5 million of restructuring charges, $3.3 million of stock-b... write-up to fair market value of inventory acquired in connection with the biosite and Cholestech acquisitions. These amounts, net of tax, have been excluded ...Inverness Medical Innovations Announces Second Quarter 2008 Results
...acquired in connection with our accounting for the biosite acquisition and $15.4 million of deferred financin...ion with our financing arrangements related to our biosite acquisition, offset by a $1.9 million foreign exch...on with our financing arrangements related to our biosite acquisition. (g) A $1.9 million foreign currency...Beckman Coulter Announces Second Quarter 2008 Results
...o Cardbeck are not subject to the rental tax. f) biosite break-up fee -- On May 17, 2007, the merger agreement to acquire Biosite, Inc. was terminated by biosite in accordance with its terms. Pursuant to the terms of the agreement, biosite paid the Company a break up fee of $54 million. Th...Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
...suffering from, heart disease and related conditions will move to Inverness biosite facility in San Diego, California. The HemoSense operation, which was acqui...bed medication used to prevent blood clots, is also expected to move to the biosite facility in San Diego. The transfers will take place in phases over the n...Inverness Medical Innovations Announces Fourth Quarter 2007 Results
... $4.8 million associated with the value of in-process research and development costs incurred in connection with our acquisition of biosite and Diamics, respectively. Purchase of in-process research and development during the year ended December 31, 2006 includes a write-off...ExonHit Builds A New Organisation
...t, Sales and Marketing of the German diagnostic company, Epigenomics. Previous to Epigenomics, Mr. Douglas was Vice President, Sales and Marketing for biosite where he was responsible for the launch of the cardiovascular diagnostic, BNP. He also served as Vice President, Marketing for Gen-Probe, was Director...Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
...Amgen follows a previous agreement that the company signed with Medarex and biosite (see press release of 18 September 2007). OGeS now has access to the two le...alise new human antibody therapeutics for the treatment of cancers and with biosite to develop a new diagnostic protein panel for relapsing colorectal cancer. ...Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors
...e Medical, Inc. and formerly Senior Vice President Corporate Development at biosite Incorporated, has joined its Board of Directors. Christopher Hibberd brin...alise new human antibody therapeutics for the treatment of cancers and with biosite to develop a new diagnostic protein panel for relapsing colorectal cancer. ...